Dulaglutide vs Tesofensine
A side-by-side research comparison of Dulaglutide and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dulaglutide | Tesofensine |
|---|---|---|
| Full name | Dulaglutide (Trulicity) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Prescription medication (FDA-approved) | Phase 3 Clinical Trial |
| Mechanism | Activates GLP-1 receptors in pancreatic beta cells (enhancing glucose-dependent insulin secretion), the hypothalamus (reducing appetite), and the GI tract (slowing gastric emptying). The Fc fusion extends half-life to ~5 days. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | ~63,000 Da | 329.4 Da |
| Half-life | ~5 days (supports weekly dosing) | 8-10 days |
| Bioavailability | ~65% subcutaneous | High (oral ~93%) |
| Typical dose | 0.75 mg - 4.5 mg once weekly | 0.25-0.5 mg |
| Frequency | Once weekly | Once daily |
| Route | Subcutaneous injection (pre-filled pen) | Oral |
Dulaglutide reported benefits
- Significant weight loss (3-5% at standard doses)
- Improved glycemic control
- Reduced cardiovascular events (REWIND trial)
- Once-weekly convenience
- Appetite suppression
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.